DOCSLIB.ORG

Resistance to Lysis of Erythrocytes Containing Haemoglobin C-Detected in a Differential White Cell Counting System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Resistance to Lysis of Erythrocytes Containing Haemoglobin C-Detected in a Differential White Cell Counting System J Clin Pathol: first published as 10.1136/jcp.36.7.816 on 1 July 1983. Downloaded from J Clin Pathol 1983;36:816-818 Resistance to lysis of erythrocytes containing haemoglobin C-detected in a differential white cell counting system F BOOTH, SUSANNE V MEAD From the Department ofHaematology, Royal Berkshire Hospital, Reading, Berkshire SUMMARY Erythrocytes containing haemoglobin C do not lyse normally in the peroxidase chan- nel of the Technicon H6000 automated cell counter. This interferes with the normal function of the channel and results in a characteristic abnormal pattern. This correlates with a reduced osmotic fragility of the red cells. A Technicon H6000 automated cell counter has Tris EDTA glycine buffer, pH 9-2. been in routine use in the haematology laboratory of Osmotic fragility of the red cells was also assessed the Royal Berkshire Hospital, Reading since March where possible, using the method of Parpart.1 1982. The machine performs an automated diffe- rential white cell count by a mechanism which relies Results on prior lysis of erythrocytes. If this fails to be copyright. achieved completely then an erroneous result is A normal "scattergram" of white cell distribution as derived. Although an infrequent occurrence, we displayed in the Technicon H6000 peroxidase chan- have found that a very high proportion of patient nel is shown in Fig. 1. In circumstances of increased samples demonstrating this phenomenon contain erythrocyte resistance to lysis there may be incom- haemoglobin C. plete red cell lysis in this channel. As a result the machine records a falsely high total white cell count Material and methods and an abnormal distribution patem in the peroxid- http://jcp.bmj.com/ ase channel. Neither is reflected in the basophil Blood samples anticoagulated with EDTA were channel where lysis has always been observed to be analysed using a Technicon H6000 automated cell complete. This is easily verified from the appropri- counter (Technicon Instruments Company Ltd). In ate function monitor trace on the machine. Of the addition to deriving red cell and platelet indices this first 28 000 patient samples analysed by the Techni- machine incorporates two white cell counting chan- con H6000 cell counter in our laboratory 22 showed incomplete red cell lysis in the peroxidase channel. nels. The erythrocytes are lysed in both prior to on September 24, 2021 by guest. Protected cytochemical staining of the white cells and subse- The Table indicates the nature of these samples. It quent analysis according to scatter and absorbance can be seen that a high proportion (17 of 22 cases) of light in optical systems. One channel employs an contained haemoglobin C. alcian blue stain to distinguish the basophil popula- The failure of red cell lysis is more marked in tion; the other links a dye to a leucocyte peroxidase patients with homozygous haemoglobin C and mediated reaction thereby distinguishing the Incidence ofincomplete red cell lysis (ofapproximately remaining major white cell groups. Different 28 000 patient samples tested) methods of red cell lysis are used in the two chan- nels; a mixture of polyoxyethylene lauryl ether (Brij No ofsamples 35) and sodium dodecylsulphate causes lysis in the Haemoglobin C trait 12 peroxidase channel while cetylpyridinium chloride Haemoglobin SC 3 Haemoglobin CC 2 has this role in the basophil channel. Haemoglobin SS* 2 Haemoglobin electrophoresis was performed on Haemoglobin AS/4-thalassaemia trait 1 relevant samples using cellulose acetate strips and Cord blood samples 2 'Failure of red cell lysis is unusual with HbSS; most cases lyse Accepted for publication 10 February 1983 normally. 816 J Clin Pathol: first published as 10.1136/jcp.36.7.816 on 1 July 1983. Downloaded from Resistance to Iysis of erythrocytes containing haemoglobin 817 Normal Haemoglobin AC .t , . M : D 01 .. .. :. :-. .,.. ..,., u ,,..-..,,. ,. L .,... E i., : .. ..,E.. O 0 I _ PERos' PEPOX: PEPOX Fig. 1 Technicon H6000 peroxidase channel graphic display appearances (scattergrams). Distribution ofleucocytes is illustrated in the normal display: N = neutrophils; M = monocytes; L = lymphocytes; E = eosinophils; D = red cell debris and platelets. Typical appearances ofthree samples containing haemoglobin C are shown. Failure oferythrocyte lysis results in a large cloud ofsmall cells, poorly stained by the peroxidaselinked dye and interpreted as "lymphocytes". In more copyright. extreme instances (haemoglobins SC and CC) the cloud extends upwards, probably as a result ofthe greater "coincidence" ofthe more numerous unlysed cells. Iffailure oflysis is sufficiently marked (as here with haemoglobin CC) the relative paucity of leucocytes compared to unlysed red cells results in a failure ofthe machine to identify the correct neutrophil cloud. http://jcp.bmj.com/ Normal range on September 24, 2021 by guest. Protected .0 - Control E ...... Hoemoglobin AC a, 2 --- .. SC IS - - - cc II 01 02 03 04 05 06 07 08 09 ('I/) No Cl Fig. 2 Erythrocyte osmotic fragility curves demonstrating increased resistance to lysis in cases ofhaemoglobin C trait (AC), haemoglobin SC disease (SC) and homozygous haemoglobin C (CC). J Clin Pathol: first published as 10.1136/jcp.36.7.816 on 1 July 1983. Downloaded from haemoglobin SC disease compared to those with It is noteworthy that the phenomenon occurs with haemoglobin C trait. This results in different scat- haemoglobin C trait since this would imply that even tergram appearances (Fig. 1) allowing these two in the heterozygous state the C haemoglobin exerts groups to be distinguished. The other conditions a very significant effect on erythrocyte fragility. We cited in the Table have shown patterns similar to have yet to find a single example of erythrocytes haemoglobin C trait. containing haemoglobin C which lysed normally in We have assessed osmotic fragility of the red cells the Technicon H6000. Furthermore, we have found in seven of the patients who have shown the little correlation between red cell morphology and phenomenon of incomplete erythrocyte lysis. In resistance to lysis in the H6000. Several of our cases every case so far tested there has been a marked of haemoglobin C trait have shown minimal or no shift in the erythrocyte fragility curve towards tendency to target cell formation and would have increased resistance to lysis (Fig. 2). passed unsuspected but for the striking abnormality In our laboratory haemoglobin electrophoresis is in the peroxidase channel. By contrast, we have carried out routinely on blood samples received tested a number of samples with marked degrees of from any patient for whom sickle haemoglobin target cell formation from patients with liver dis- screening is requested, or who is known to be from ease, none of which has shown any failure of lysis. an ethnic background where there is a significant The patterns obtained from cases of haemoglobin likelihood of variant haemoglobins being detected. C trait are sufficiently different from those of In addition, samples are electrophoresed if the haemoglobin SC disease or homozygous haemoglo- blood film reveals any suspicion of a haemog- bin C disease to allow their distinction. lobinopathy. Despite this extensive screening 8/17 In the presence of a normal haemoglobin or mild cases of haemoglobin C discovered during the anaemia, the finding of a positive sickle haemoglo- period of this survey were found incidentally as a bin screen together with failure of lysis of erythro- result of non-lysis of red cells in the Technicon cytes in the H6000 peroxidase channel is highly sug- H6000. Every specimen tested in the H6000 which gestive of haemoglobin SC disease. Since this diag- has been known or subsequently shown to contain nosis has potentially important consequences, for haemoglobin C (trait, disease or interaction with instance in the patient about to undergo general other haemoglobin) has shown resistance to red cell anaesthesia, then this rapid diagnostic technique has copyright. lysis in the peroxidase channel sufficient to cause a some clinical value to offset its original observation characteristic abnormal pattern. as an unwanted artefact in the peroxidase channel. The finding ab initio of a pattern suggestive of Discussion haemoglobin SC or CC disease, which has now occurred on three occasions in our laboratory, is an The early studies on characterisation of haemoglo- indication in the first instance to perform a sickle bin C included demonstration of the fact that ery- haemoglobin screen (a positive result strongly sug- http://jcp.bmj.com/ throcytes containing this variant haemoglobin gesting the diagnosis of haemoglobin SC disease) showed increased resistance to osmotic lysis.2 Gott- and subsequently to proceed to haemoglobin elec- fried and Robertson,3 and Posteraro and Gottfried,4 trophoresis. showed by means of a glycerol lysis test (GLT) that several haemoglobinopathies are associated with a We thank the haematology staff for technical assis- decrease in erythrocyte osmotic fragility, and that tance and performing the osmotic fragility studies, this could also be the case with severe chronic renal and Professor D Robertson Smith and Dr CJ Barton on September 24, 2021 by guest. Protected disease, fetal (cord) red cells, and occasionally with for advice and help given in interpretation of results iron deficiency anaemia. Patients with and preparation of the manuscript. ,8-thalassaemia trait constituted the largest single group. We have never found that thalassaemia trait in itself results in non-lysis of red cells in the Techni- Referewe con H6000, and indeed we have tested samples from Parpart AK, Lorenz PB, Parpart ER, Gregg JR, Chase AM. The four patients with f-thalassaemia major none of osmotic resistance (fragility) of human red ceils. J Clin Invest which failed to lyse normally. It is, however, of note 1947;26:636. that the only samples reported by Gottfried et al to 2 Kaplan E, Zuelzer WW, Neel JV. Further studies on Haemoglo- bin C. Blood 1953;8:735-46. contain haemoglobin C (three patients with haemo- 3Gottfried EL, Robertson NA.
Load more

Recommended publications
  • 1 Brief Report: the Virucidal Efficacy of Oral Rinse Components Against SARS-Cov-2 in Vitro Evelina Statkute1†, Anzelika Rubin
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Brief Report: The Virucidal Efficacy of Oral Rinse Components Against SARS-CoV-2 In Vitro Evelina Statkute1†, Anzelika Rubina1†, Valerie B O’Donnell1, David W. Thomas2† Richard J. Stanton1† 1Systems Immunity University Research Institute, Division of Infection & Immunity, School of Medicine, Heath Park, Cardiff, CF14 4XN 2Advanced Therapies Group, School of Dentistry, Cardiff University, Heath Park, Cardiff CF14 4XY, UK †These authors contributed equally * Correspondence: [email protected], [email protected] Running title: Virucidal Activity of Mouthwashes Keywords: SARS-CoV2, mouthwash, lipid, envelope Disclosure: Venture Life Group plc provided information on mouthwash formulations employed in the study, but had no role in funding, planning, execution, analysis or writing of this study. A separate study funded to Cardiff University by Venture Life Group is assessing in vivo efficacy of CPC in patients with COVID19. The investigators declare no direct conflicts exist. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.
    [Show full text]
  • In Vivo Evaluation of the Virucidal Efficacy of Chlorhexidine and Povidone-Iodine Mouthwashes Against Salivary SARS-Cov-2
    medRxiv preprint doi: https://doi.org/10.1101/2021.03.07.21252302; this version posted March 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Title: In vivo evaluation of the virucidal efficacy of Chlorhexidine and Povidone-iodine mouthwashes against salivary SARS-CoV-2. Rola Elzein1*, Fadi Abdel-Sater2*, Soha Fakhreddine3, Pierre Abi Hanna3, Rita Feghali4, Hassan Hamad5, Fouad Ayoub6 ¹Department of Pediatric Dentistry and Public Dental Health, Faculty of Dental Medicine, Lebanese University, Beirut, Lebanon 2Laboratory of Cancer Biology and Cellular Immunology, Department of Biological Sciences, Faculty of Sciences, Lebanese University, Beirut, Lebanon 3Infectious Diseases division, Rafik Hariri University Hospital, Beirut, Lebanon 4Department of Laboratory Medicine, Rafik Hariri University Hospital, Beirut, Lebanon 5Medical care Laboratory, Faculty of Public Health IV, Lebanese University, Zahle, Lebanon 6Department of Forensic Odontology, Human Identification and Anthropology, Faculty of Dental Medicine, Lebanese University, Beirut, Lebanon *CORRESPONDING AUTHORS: Rola ELZEIN; Mobile number: 009613252480; Email address: [email protected] Fadi Abdelsater; Mobile number: 009613781176; Email address: [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.03.07.21252302; this version posted March 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • A Screening-Based Approach to Circumvent Tumor Microenvironment
    JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL.
    [Show full text]
  • Expert Recommendations for Prevention, Treatment and Care of Oral Ulcers and Other Mucosal Diseases During the Outbreak of COVID
    Chin J Dent Res 2020;23. Online March 3, 2020. Available at: http://cjdr.cndent.com Expert Recommendations for Prevention, Treatment and Care of Oral Ulcers and other Mucosal Diseases during the Outbreak of COVID-19 Society of Oral Mucosal Diseases, Chinese Stomatological Association1 In December 2019, some new cases of coronavirus disease-19 (COVID-19) were found in Wuhan City, Hubei Province, China. The number of infected cases increased rapidly and spread continuously at home and abroad. Tens of thousands of medical staff throughout the country have rushed to Wuhan to invest in intensive medical treatment. Because of high mental tension and work intensity, unable to drink water for hours after entering the isolation ward and insufficient sleep, they might suffer from oral mucosal ulcers and other oral mucosal diseases. It is known that not only medical staff, but also police officers, community workers, long-term family members, and even patients with mild COVID-19, as well as those with oral mucosal disease in the past, all claim they feel uncomfortable with oral mucosal disorders, such as oral ulcer caused by great mental pressure, which mainly include recurrent aphthous ulcer (RAU), chronic cheilitis and oral lichen planus. This article will give some suggestions on the prevention and care of the oral mucosal diseases above mentioned during fighting againstOnline COVID-19, focusing on the measures First to deal with the oral mucosal damage caused by stress response. Key words: coronavirus disease-19 (COVID-19), recurrent aphthous ulcer, cheilitis, oral lichen planus, stress response 1 Corresponding author: Prof. Hong Wei LIU, Department of Oral Medicine, Peking University School and Hospital of Stomatology, 22# Zhongguancun South Avenue, Haidian District, Beijing 100081, P.R.
    [Show full text]
  • Inactivation of SARS-Cov-2 Through Treatment with the Mouth Rinsing Solutions Viruprox® and Bacterx® Pro
    microorganisms Communication Inactivation of SARS-CoV-2 through Treatment with the Mouth Rinsing Solutions ViruProX® and BacterX® Pro Julia Koch-Heier 1,†, Helen Hoffmann 1,†, Michael Schindler 2 , Adrian Lussi 3,4 and Oliver Planz 1,* 1 Interfaculty Institute for Cell Biology, Department of Immunology, Eberhard Karls University of Tuebingen, 72076 Tuebingen, Germany; [email protected] (J.K.-H.); [email protected] (H.H.) 2 Institute for Medical Virology and Epidemiology of Viral Disease, Department of Molecular Virology, 72076 Tuebingen, Germany; [email protected] 3 Department of Operative Dentistry and Periodontology, University Medical Centre, 79106 Freiburg, Germany; [email protected] 4 School of Dental Medicine, University of Bern, 3010 Bern, Switzerland * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic effects daily dental work. Therefore, infection control measures are necessary to prevent infection of dental personnel during dental treatments. The use of a preprocedural mouth rinse with chlorhexidine (CHX), cetylpyridinium chloride (CPC), or hydrogen peroxide (H2O2) solution for 30–60 s may reduce the viral load and may protect the personnel in a dental practice. In the present study the ® virucidal effect of the mouth rinsing solutions ViruProX with 0.05% CPC and 1.5% H2O2 and Citation: Koch-Heier, J.; Hoffmann, BacterX® pro containing 0.1% CHX, 0.05% CPC, and 0.005% sodium fluoride (F-) was investigated H.; Schindler, M.; Lussi, A.; Planz, O. in vitro. The mouth rinsing solutions successfully inactivated infectious SARS-CoV-2 particles, the Inactivation of SARS-CoV-2 through causative agent of coronavirus disease 2019 (COVID-19), within 30 s.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Release of Antimicrobial Agents from Glass Ionomer Cements
    Y T E I C O S L BALKAN JOURNAL OF STOMATOLOGY A ISSN 1107 - 1141 IC G LO TO STOMA Release of Antimicrobial Agents from Glass Ionomer Cements SUMMARY Aleksandar Dimkov, Elizabeta Gjorgievska, The aim of this study was to determine the level of antimicrobial Aleksandar Fildishevski agents Benzalkonium Chloride and Cetylpyridinium Chloride released Faculty of Dentistry, Clinic for Pediatric and from ChemFlex, a conventional glass ionomer cement (GIC). The main null Preventive Dentistry, Skopje, FYROM hypothesis tested was that there is no release of antimicrobial agents into the surrounding medium. 3 groups of the conventional ChemFlex GIC of 5 samples each, with Benzalconium Chloride and CPC incorporated, were prepared - each group with a different percentage of the agents (1%, 2%, and 3%). The determination of the quantity of the antimicrobial agents was done by an UV- Spectrophotometer. The measurements were performed at 11 successive time intervals. The results of the statistical analysis point out that it is possible to incorporate these antimicrobial agents in conventional GIC, especially when the added percentage of the antimicrobial agents is 3%. ORIGINAL PAPERS (OP) Keywords: GIC; Antimicrobial Agents; UV-Spectrophotometry Balk J Stom, 2012; 16:84-89 Introduction application9. There are several studies dealing with the effect of incorporating chlorhexidine in different Because of the relatively frequent occurrence of concentrations and its combinations in GIC to improve recurrent caries after a restorative treatment, and because their antimicrobial properties10-14. of the huge number of cariogenic microorganisms There are only a few data in the literature referring existing in the oral cavity, which present a potential to the incorporation and release of other antimicrobial risk factor regarding the development of new carious components in GIC.
    [Show full text]
  • Efficacy of Commercial Mouth-Rinses on SARS-Cov-2 Viral Load in Saliva: Randomized Control Trial in Singapore
    medRxiv preprint doi: https://doi.org/10.1101/2020.09.14.20186494; this version posted September 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: Randomized Control Trial in Singapore Chaminda J. Seneviratne1,2*+, Preethi Balan1,2+, Karrie Ko Kwan Ki3+, Nadeeka S Udawatte1, Deborah Lai3, Dorothy Ng Hui Lin4 , Indumathi Venkatachalam4, Jay Lim Kheng Sit5, Ling Moi Lin6, Lynette Oon3, Goh Bee Tin1,2, Jean Sim Xiang Ying4*+ 1Singapore Oral Microbiomics Initiative, National Dental Research Institute Singapore (NDRIS), National Dental Centre Singapore, 2Oral Health ACP, Duke NUS Medical School, Singapore; 3Department of Microbiology, 4Department of Infectious Diseases, 5Department of Urology, 6Department of Infection Prevention and Epidemiology, Singapore General Hospital, Singapore +Equal contribution *Corresponding authors Associate Prof. Chaminda Jaya Seneviratne, Lead Principal Investigator, Singapore Oral Microbiomics Initiative, National Dental Research Institute Singapore (NDRIS), National Dental Centre Singapore, SingHealth Oral Health ACP, Duke NUS Medical School, Singapore, [email protected] Dr. Jean Sim Xiang Ying, Consultant, Department of Infectious Diseases, Singapore General Hospital, SingHealth, Singapore [email protected] Keywords: COVID-19, SARS-CoV-2, mouth-rinses, saliva, clinical trial NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2020.09.14.20186494; this version posted September 18, 2020.
    [Show full text]
  • Known Bioactive Library: Microsource 1 - US Drug Collection
    Known Bioactive Library: Microsource 1 - US Drug Collection ICCB-L ICCB-L Vendor Vendor Compound Name Bioactivity Source CAS Plate Well ID antifungal, inhibits Penicillium 2091 A03 Microsource 00200046 GRISEOFULVIN 126-07-8 mitosis in metaphase griseofulvum 3505-38-2, 486-16-8 2091 A04 Microsource 01500161 CARBINOXAMINE MALEATE antihistaminic synthetic [carbinoxamine] 2091 A05 Microsource 00200331 SALSALATE analgesic synthetic 552-94-3 muscle relaxant 2091 A06 Microsource 01500162 CARISOPRODOL synthetic 78-44-4 (skeletal) antineoplastic, 2091 A07 Microsource 00210369 GALLIC ACID insect galls 149-91-7 astringent, antibacterial 66592-87-8, 50370-12- 2091 A08 Microsource 01500163 CEFADROXIL antibacterial semisynthetic 2 [anhydrous], 119922- 89-9 [hemihydrate] Rheum palmatum, 2091 A09 Microsource 00211468 DANTHRON cathartic 117-10-2 Xyris semifuscata 27164-46-1, 25953-19- 2091 A10 Microsource 01500164 CEFAZOLIN SODIUM antibacterial semisynthetic 9 [cefazolin] glucocorticoid, 2091 A11 Microsource 00300024 HYDROCORTISONE adrenal glands 50-23-7 antiinflammatory 64485-93-4, 63527-52- 2091 A12 Microsource 01500165 CEFOTAXIME SODIUM antibacterial semisynthetic 6 [cefotaxime] 2091 A13 Microsource 00300029 DESOXYCORTICOSTERONE ACETATE mineralocorticoid adrenocortex 56-47-3 58-71-9, 153-61-7 2091 A14 Microsource 01500166 CEPHALOTHIN SODIUM antibacterial semisynthetic [cephalothin] 2091 A15 Microsource 00300034 TESTOSTERONE PROPIONATE androgen, antineoplastic semisynthetic 57-85-2 24356-60-3, 21593-23- 2091 A16 Microsource 01500167 CEPHAPIRIN SODIUM
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Cetylpyridinium Chloride As a Tool Against COVID-19
    Int. J. Odontostomat., 15(1):27-30, 2021. Cetylpyridinium Chloride as a Tool Against COVID-19 Cloruro de Cetilpiridinio como Herramienta para Combatir el COVID-19 Sebastián Pérez-Errázuriz1; Eugenio Velasco-Ortega1; Álvaro Jiménez-Guerra1 & Eduardo Aguilera-Navarro2 PÉREZ-ERRÁZURIZ, S.; VELASCO-ORTEGA, E.; JIMÉNEZ-GUERRA, A. & AGUILERA-NAVARRO, E. Cetylpyridinium chloride as a tool against COVID-19. Int. J. Odontostomat., 15(1):27-30, 2021. ABSTRACT: As a part of bringing knowledge to healthcare professional, our team searched in the literature the effectiveness of Cetylpyridinium Chloride over SARS-CoV-2. Objectives: Explore the efficacy of Cetylpyridinium Chloride as a mouthwash in the dental attention. Methods: A literature search was realized in PubMed (MEDLINE), with the focusing on the following words: “Cetylpyridinium Chloride”, “COVID-19”, "Mouthwash”, up to June 30, 2020. Results: There is a few information of this biocide over lower and upper airway affection, and other microorganisms. The effect of Cetylpyridinium Chloride over SARS-CoV-2 has not been proved. Although different guidelines recommend oxidative agents as a mouthwash before dental attention. Conclusion: Cetylpyridinium chloride is a cationic biocide widely used as a disinfectant in dentistry and as a mouthwash. Nevertheless, more research is needed, to know the effectiveness of CPC over SARS-CoV-2. KEYWORDS: Cetylpyridinium Chloride, COVID-19, mouthwash. INTRODUCTION RESULTS Inhalation of infected aerosols is the main form SARS CoV-2. Experts of the International of transmission. The mouth is considered an open Committee on Taxonomy of Viruses are calling: gate to infectious agents, and it is directly related SARS-CoV-2, because it has the exact same entry with SARS-CoV-2 virus.
    [Show full text]
  • Micellar Growth in Cetylpyridinium Chloride/Alcohol System: Role of Long Chain Alcohol, Electrolyte and Surfactant Head Group
    J Surfact Deterg (2016) 19:849–860 DOI 10.1007/s11743-016-1826-7 ORIGINAL ARTICLE Micellar Growth in Cetylpyridinium Chloride/Alcohol System: Role of Long Chain Alcohol, Electrolyte and Surfactant Head Group 1 2 3 4 Jasila Karayil • Sanjeev Kumar • Yeshayahu Talmon • P. A. Hassan • 5 1 B. V. R. Tata • Lisa Sreejith Received: 29 October 2015 / Accepted: 25 April 2016 / Published online: 13 May 2016 Ó AOCS 2016 Abstract The microstructural transition of aqueous 0.1 M (UCST) [ the lower critical solution temperature (LCST), cetylpyridinium chloride (CPC) in the combined presence reminiscence of nicotine-water system. The role of sur- of salt KBr and long chain alcohol (C9OH-C12OH) has factant head group on the structural evolution was revealed been studied as a function of alcohol concentration, elec- by comparing the present results with our previous report trolyte concentration and temperature. The viscosity of the for similar micellar system, CTAB/KBr/long chain alcohol. CPC/KBr micellar system showed a peaked behavior with alcohol concentration (C0), due to alcohol induced struc- Keywords CPC Á Long chain alcohol Á UCST and LCST tural transition, which was confirmed by dynamic light scattering (DLS) and rheological analysis. Besides C0, the chain length of alcohol (n) was found to show a remarkable Introduction effect on the micellization behavior of CPC/KBr system. It was observed that the ability of alcohol to induce micelle By virtue of their amphiphilic nature, surfactant molecules growth diminishes with n, which was well supported by can self-assemble into a great variety of microstructures in viscosity, rheology and DLS measurements.
    [Show full text]